Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, a… Read more
Gujarat Themis Biosyn Limited (GUJTHEM) - Net Assets
Latest net assets as of September 2025: ₹2.64 Billion INR
Based on the latest financial reports, Gujarat Themis Biosyn Limited (GUJTHEM) has net assets worth ₹2.64 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.77 Billion) and total liabilities (₹1.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹2.64 Billion |
| % of Total Assets | 70.2% |
| Annual Growth Rate | 33.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.59 |
Gujarat Themis Biosyn Limited - Net Assets Trend (2022–2025)
This chart illustrates how Gujarat Themis Biosyn Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gujarat Themis Biosyn Limited (2022–2025)
The table below shows the annual net assets of Gujarat Themis Biosyn Limited from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.48 Billion | +23.34% |
| 2024-03-31 | ₹2.01 Billion | +35.02% |
| 2023-03-31 | ₹1.49 Billion | +44.35% |
| 2022-03-31 | ₹1.03 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gujarat Themis Biosyn Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 153.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.37 Billion | 95.55% |
| Common Stock | ₹108.97 Million | 4.39% |
| Other Components | ₹1.57 Million | 0.06% |
| Total Equity | ₹2.48 Billion | 100.00% |
Gujarat Themis Biosyn Limited Competitors by Market Cap
The table below lists competitors of Gujarat Themis Biosyn Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zig Sheng Industrial Co Ltd
TW:1455
|
$96.80 Million |
|
Ekovest Bhd
KLSE:8877
|
$96.80 Million |
|
Tunas Baru Lampung Tbk
JK:TBLA
|
$96.84 Million |
|
Acusensus Ltd
AU:ACE
|
$96.85 Million |
|
Guangdong Hongming Intelligent Joint Stock Co. Ltd.
SHE:301105
|
$96.74 Million |
|
China Electric Manufacturing Corp
TW:1611
|
$96.73 Million |
|
Dah San Electric Wire & Cable Co Ltd
TW:1615
|
$96.72 Million |
|
SV Investment Corporation
KQ:289080
|
$96.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gujarat Themis Biosyn Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,013,761,000 to 2,483,819,000, a change of 470,058,000 (23.3%).
- Net income of 487,717,000 contributed positively to equity growth.
- Dividend payments of 212,383 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹487.72 Million | +19.64% |
| Dividends Paid | ₹212.38K | -0.01% |
| Other Changes | ₹-17.45 Million | -0.7% |
| Total Change | ₹- | 23.34% |
Book Value vs Market Value Analysis
This analysis compares Gujarat Themis Biosyn Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 28.80x to 11.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹9.48 | ₹273.05 | x |
| 2023-03-31 | ₹13.69 | ₹273.05 | x |
| 2024-03-31 | ₹18.48 | ₹273.05 | x |
| 2025-03-31 | ₹22.79 | ₹273.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gujarat Themis Biosyn Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.64%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.34%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.21x
- Recent ROE (19.64%) is below the historical average (32.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 42.22% | 38.20% | 0.93x | 1.19x | ₹332.92 Million |
| 2023 | 38.87% | 39.13% | 0.89x | 1.12x | ₹430.54 Million |
| 2024 | 29.38% | 34.84% | 0.77x | 1.10x | ₹390.26 Million |
| 2025 | 19.64% | 32.34% | 0.50x | 1.21x | ₹239.34 Million |
Industry Comparison
This section compares Gujarat Themis Biosyn Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gujarat Themis Biosyn Limited (GUJTHEM) | ₹2.64 Billion | 42.22% | 0.42x | $96.78 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |